Gemopatrilat
 | |
| Clinical data | |
|---|---|
| Other names | BMS-189921 |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C19H26N2O4S |
| Molar mass | 378.49g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Gemopatrilat(INN)[1]is an experimentaldrugthat was never marketed.[2]It acts as a vasopeptidaseinhibitor.[3][4]It inhibits bothangiotensin-converting enzyme(ACE) and neutral endopeptidase (neprilysin).[5]
References
[edit]- ^"International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 46"(PDF).World Health Organization. p. 200.Retrieved2 March2017.
- ^"Gemopatrilat".AdisInsight.
Highest Development Phases: Discontinued
- ^Laverman GD, Van Goor H, Henning RH, De Jong PE, De Zeeuw D, Navis G (January 2003)."Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes".Kidney International.63(1): 64–71.doi:10.1046/j.1523-1755.2003.00708.x.PMID12472769.
- ^Wait JC, Vaccharajani N, Mitroka J, Jemal M, Khan S, Bonacorsi SJ, et al. (June 2006). "Metabolism of [14C]gemopatrilat after oral administration to rats, dogs, and humans".Drug Metabolism and Disposition.34(6): 961–70.doi:10.1124/dmd.105.007500.PMID16540589.S2CID25629874.
- ^Hubner RA, Kubota E, Casley DJ, Johnston CI, Burrell LM (May 2001). "In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat".Journal of Hypertension.19(5): 941–6.doi:10.1097/00004872-200105000-00015.PMID11393678.S2CID9162678.
 | Thisdrugarticle relating to thecardiovascular systemis astub.You can help Wikipedia byexpanding it. |